{
  "report_rows": [
    {
      "kpi": "Skyrizi Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$5.60B vs. cons $5.44B",
      "confidence": "HIGH"
    },
    {
      "kpi": "Neuroscience Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$3.20B vs. cons $3.12B",
      "confidence": "HIGH"
    },
    {
      "kpi": "Adj. EPS ex-IPR&D (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$3.68 vs. cons $3.61",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Total Revenue (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$67.7B vs. cons $67.4B",
      "confidence": "HIGH"
    },
    {
      "kpi": "Adj. EPS ex-IPR&D (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$14.45 midpoint vs. cons $14.09",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 Revenue",
      "prediction": "BETTER",
      "answer": "guide ~$17.0B vs. cons $16.8B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Aesthetics tone (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "maintained ~$5.0B, cautious tone vs. cons $4.98B",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 FY raise forces H2 estimate revisions upward; implied H2 ~$2B above current consensus pulls sell-side models higher over 3-5 days",
  "day5_confidence": "MEDIUM"
}